Cyclosporin, leflunomide and nitrogen mustard

Bailliere's Clinical Rheumatology

Volumn 9, Issue 4, 1995, Pages 711-729

  Furst, Daniel E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CHLORMETHINE; CYCLOSPORIN; LEFLUNOMIDE; ALKYLATING AGENT; ISOXAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALOPECIA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GINGIVITIS; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; INFECTION; LIVER TOXICITY; NEPHROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; TREMOR; ABSORPTION; DRUG COMBINATION; METABOLISM; TISSUE DISTRIBUTION;

ABSORPTION; ALKYLATING AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; ISOXAZOLES; MECHLORETHAMINE; TISSUE DISTRIBUTION;

EID: 0028839425     PISSN: 09503579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3579(05)80310-3     Document Type: Article

References (47)

1. A randomized double-blind trial of cyclosporin and azathioprine in refractory RA
2. Cyclosporin
3. Chemotherapy and antibiotic fluid standardization and fluid minimums
4. Malignancies in RA patients treated with cyclosporin A
5. Cyclosporine pharmacokinetic drug interactions
6. Leflunomide: a novel immunomodulatory drug
7. Antiproliferative agents and drugs used for immunosuppression
8. Graperfruit juice and cyclosporin A blood concentrations in patients with rheumatic diseases
9. Cyclosporine: nephrotoxic effects and guidelines for safe use in patients with RA
10. Nitrogen mustard as induction therapy for RA: clinical and immunological effects
11. Efficacy and safety of leflunomide in the treatment of patients with RA
12. Cyclosporin in rheumatoid arthritis: a double-blind, placebo controlled study in 52 patients
13. Bromocriptine and cyclosporin A combination therapy in RA
14. NITROGEN MUSTARD IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
15. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders
16. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. results of a 48-week multicenter study comparing low-dose cyclosporine with placebo
17. Coordinate expression of src family protooncogenes in T cell activation and its modulation by cyclosporine
18. Lymphokine gene expression in vivo is inhibited by cyclosporin A
19. Renal morphology after cyclosporin A therapy in RA patients
20. TREATMENT OF RHEUMATOID ARTHRITIS WITH NITROGEN MUSTARD
21. The treatment of persistent synovitis with nitrogen mustard
22. Nitrogen mustard and methylprednisolone in severe RA
23. Nitrogen mustard in severe RA
24. Comparison of cyclosporin A and azathioprine in the treatment of RA—results of a double-blind, multi-center study
25. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis
26. A randomized, double-blind, 24-week, controlled study of low-dose cyclosporine versus chloroquine for early RA
27. Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with RA
28. DNA as a target of alkylating carcinogens
29. Cyclosporin A nephropathy in patients with RA
30. Effects of nitrogen mustard in patients with RA
31. The effect of food on cyclosporine absorption
32. Clinical pharmacokinetics of cyclosporin
33. Long-term adminstration of leflunomide to patients with RA
34. Weekly administration of leflunomide to patients with active RA
35. The effects of cyclosporin A on bone and cartilage
36. Intravenous administration of nitrogen mustard alone and with corticotropin for RA
37. Sulindac-induced elevation of serum cyclosporin concentration
38. Low dose cyclosporin versus placebon in patients with RA
39. A multi-centre, double-blind, randomized trial of low-dose cyclosporin and placebo therapy in combination with methotrexate in patients with severe RA
40. Comparison of cyclosporine and D-penicillamine for RA: a randomized, double-blind, multicenter study
41. Prolonged remission of tumor-stage mycosis fungoides by topical immunotherapy
42. Diurnal variation in cylcosporin kinetics
43. The use of nitrogen mustard in the treatment of serious effusions of neoplastic origins
44. Pharmacokinetic drug interactions with cyclosporin
45. Immunological actions of cyclosporin A in rheumatoid arthritis